16-May-2024
TipRanks (Wed, 15-May 10:10 PM ET)
Deciphera Pharmaceuticals: Hold Rating Amid Acquisition and Concerns Over Qinlock Sales
TipRanks (Tue, 14-May 4:37 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AGS, HCP, DCPH
PRNewswire (Mon, 13-May 5:13 PM ET)
Deciphera Pharmaceuticals: A Hold Rating Amidst Ono Pharmaceutical Acquisition Offer
TipRanks (Mon, 13-May 10:06 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, IONM, DPSI
PRNewswire (Fri, 10-May 1:52 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HCP, TBNK
Globe Newswire (Thu, 9-May 12:17 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DCPH, HTLF, DPSI, UNIT
Globe Newswire (Sat, 4-May 9:24 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, DCPH, HTLF, TBNK
PRNewswire (Thu, 2-May 12:34 PM ET)
Business Wire (Wed, 1-May 6:13 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HRT, DCPH, UMBF
Globe Newswire (Wed, 1-May 9:42 AM ET)
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Deciphera Pharmaceuticals trades on the NASDAQ stock market under the symbol DCPH.
As of May 16, 2024, DCPH stock price was flat at $25.45 with 1,282,471 million shares trading.
DCPH has a beta of 1.45, meaning it tends to be more sensitive to market movements. DCPH has a correlation of 0.07 to the broad based SPY ETF.
DCPH has a market cap of $2.20 billion. This is considered a Mid Cap stock.
Last quarter Deciphera Pharmaceuticals reported $45 million in Revenue and -$.52 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.03.
In the last 3 years, DCPH stock traded as high as $38.91 and as low as $6.51.
The top ETF exchange traded funds that DCPH belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
DCPH has outperformed the market in the last year with a return of +86.0%, while the SPY ETF gained +30.5%. In the last 3 month period, DCPH beat the market returning +62.4%, while SPY returned +6.2%. However, in the most recent 2 weeks DCPH has underperformed the stock market by returning +0.3%, while SPY returned +4.7%.
DCPH support price is $24.89 and resistance is $26.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DCPH stock will trade within this expected range on the day.